PO.ET09.10 · 实验与分子治疗
脾酪氨酸激酶作为髓母细胞瘤的新型靶点
Spleen tyrosine kinase as a novel target in medulloblastoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：3型髓母细胞瘤（MB）是最具侵袭性的儿童脑肿瘤，其特征为MYC癌基因扩增、预后差以及对标准放化疗耐药，亟需新型治疗靶点。脾酪氨酸激酶（SYK）被认为是多种血液系统和实体恶性肿瘤中重要的癌基因和信号介导分子，参与增殖和存活通路。由于MYC蛋白在很大程度上不可成药，我们基于SYK在其他恶性肿瘤中与MYC驱动的转录程序协同作用的报道，将其作为潜在治疗靶点进行研究。
方法：由于MYC不可成药，我们探索靶向脾酪氨酸激酶（SYK）——MYC依赖通路的一个组分。我们在MYC扩增的MB细胞系（HD-MB03和D425）中采用药物抑制（R406、Bay61、Fostamatinib），通过MTT实验和Western blot评估细胞活力和MYC蛋白水平。我们还评估了SYK抑制与顺铂（cisplatin）联合在D425细胞中的治疗潜力。未来工作将在体外（通过shRNA敲低、ChIP、RNA测序）阐明分子机制（转录/翻译），并在患者来源异种移植（PDX）小鼠模型中评估治疗疗效。
数据：SYK抑制以剂量依赖方式显著降低HD-MB03细胞活力（R406在5 μM时将活力降至约18%），并在HD-MB03和D425细胞中均引起MYC蛋白的明显下调。至关重要的是，SYK抑制剂与标准化疗药物顺铂联合在D425细胞中显示出协同效应，提示存在潜在的化疗增敏机制。这些初步数据有力地支持了SYK在MYC驱动的MB肿瘤发生中的关键作用。
结论：初步发现支持SYK在侵袭性髓母细胞瘤中作为MYC驱动肿瘤发生的关键调控因子这一假说。在D425细胞中将SYK抑制剂与顺铂联合时观察到的协同毒性，凸显了一种潜在的化疗增敏机制。使用SYK抑制剂靶向SYK-MYC轴，尤其是与现有化疗联合，为克服治疗耐药、显著改善高危MYC驱动型髓母细胞瘤患者预后提供了一种强有力且可临床转化的策略。
查看英文原文 English abstract
Background: Group 3 medulloblastoma (MB) is the most aggressive pediatric brain tumor, characterized by MYC oncogene amplification, poor prognosis, and resistance to standard chemoradiation, necessitating novel therapeutic targets. Spleen Tyrosine Kinase (SYK) is known as an important oncogene and signaling mediator in various hematologic and solid malignancies, contributing to proliferation and survival pathways. Because MYC proteins remain largely undruggable, we investigated SYK as a potential therapeutic target based on its reported cooperation with MYC-driven transcriptional programs in other malignancies.
Methods: Since MYC is undruggable, we explored targeting the Spleen Tyrosine Kinase (SYK), a component of MYC-dependent pathways. We used pharmacological inhibition (R406, Bay61, Fostamatinib) in MYC-amplified MB cell lines (HD-MB03 and D425) to assess cell viability and MYC protein levels via MTT assays and Western blotting. We also evaluated the therapeutic potential of SYK inhibition combined with cisplatin in D425 cells. Future work will elucidate the molecular mechanism (transcription/translation) in vitro (via shRNA knockdown, ChIP, RNA sequencing) and evaluate therapeutic efficacy in patient-derived xenograft (PDX) mouse models.
Data: SYK inhibition significantly reduced HD-MB03 cell viability in a dose-dependent manner (R406 reduced viability to ~18% at $5 μM) and caused distinct downregulation of MYC protein in both HD-MB03 and D425 cells. Crucially, the combination of SYK inhibitors with the standard chemotherapeutic agent cisplatin showed a synergistic effect in D425 cells, suggesting a potential chemo sensitization mechanism. These preliminary data strongly support the critical role of SYK in MYC-driven MB oncogenesis.
Conclusions: The preliminary findings support the hypothesis that SYK acts as a key regulator of MYC-driven tumorigenesis in aggressive medulloblastoma. The observed synergistic toxicity when combining SYK inhibitors with cisplatin in D425 cells highlights a prospective chemo-sensitization mechanism. Targeting the SYK-MYC axis using SYK inhibitors, especially in combination with existing chemotherapies, offers a powerful, clinically translatable strategy to overcome treatment resistance and significantly improve outcomes for patients with high-risk, MYC-driven medulloblastoma
利益披露 Disclosure
V. Salvi, None..
G. Naik, None..
A. Sharma, None.